Long-term follow up of a phase 1/2 study of ProSavin, a lentiviral vector gene therapy for Parkinson’s disease

[Farooqji]

Some good news

liebertpub.com/doi/10.1089/...

[park_bear]

Out of 15 patients, " Ninety-six drug-related adverse events were reported (87 mild, 6 moderate, 3 severe) of which more than half occurred in the first year. The most common drug-related events were dyskinesias (33 events, 11 patients) and on-off phenomena (22 events, 11 patients)." Also, apparently subsequent to this therapy, "Eight patients received deep brain stimulation at different time points and their subsequent assessments continued to assess safety." So for least those eight out of the 15, the gene therapy was not sufficient.